<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954705</url>
  </required_header>
  <id_info>
    <org_study_id>RC15_0454</org_study_id>
    <nct_id>NCT02954705</nct_id>
  </id_info>
  <brief_title>MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS</brief_title>
  <acronym>MINERVA</acronym>
  <official_title>MICRO-RNAs OF NEUTROPHILS IN RENAL ANCA-ASSOCIATED VASCULITIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INSERM UMRS-1064</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Activation of neutrophils by ANCA (&quot;Anti-Neutrophil Cytoplasm Antibodies&quot;) and subsequent&#xD;
      microvascular endothelial cell damage is the main feature of ANCA-associated vasculitis&#xD;
      (AAV), a severe autoimmune disease that often targets the kidney. There is no specific&#xD;
      treatment for AAV to date and 25% of patients with renal damage evolve towards end-stage&#xD;
      renal disease, requiring dialysis and kidney transplantation. In addition, there is no&#xD;
      reliable biological marker of the disease activity available, which makes the diagnostic,&#xD;
      follow-up and treatment of patients difficult. Therefore, the identification of new&#xD;
      therapeutic targets and non-invasive biomarkers constitutes a major clinical challenge to&#xD;
      improve AAV patients care and to ameliorate their renal outcome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expression profile of miRNAs in patients with AAV in circulating neutrophils, plasma and urine.</measure>
    <time_frame>6 month after maintenance treatment</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">63</enrollment>
  <condition>ANCA-associated Vasculitis</condition>
  <arm_group>
    <arm_group_label>Group AAV</arm_group_label>
    <description>Patients recruited from the Nantes University Hospital. 50 milliliter of blood and 10mL of urine are collected from these patients during levies in clinical visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group control</arm_group_label>
    <description>People recruited from the &quot;Etablissement français du sang&quot; (French blood establishment ).&#xD;
10 milliliter of blood are collected from these donors</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non interventional study</intervention_name>
    <description>This is a non interventional study because all levies are performed during visit planned for the care of patients.</description>
    <arm_group_label>Group AAV</arm_group_label>
    <arm_group_label>Group control</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      50 mL of blood and 10 mL of urine by patient&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This will be done in total in 50 patients with ANCA-associated vasculitis (AAV) and 20&#xD;
        control patients. Among the 50 patients with AAV, 30 patients will be newly diagnosed and&#xD;
        20 already followed for AAV&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for patients:&#xD;
&#xD;
          -  Adult patients aged over 18 years&#xD;
&#xD;
          -  Patients with Granulomatosis with polyangiitis or microscopic polyangiitis meeting the&#xD;
             criteria of Chapel Hill.&#xD;
&#xD;
          -  corticosteroid treatment &lt;20 mg / day.&#xD;
&#xD;
          -  Informed consent: oral for participation in research and writing for biological&#xD;
             collection.&#xD;
&#xD;
        Inclusion Criteria for controls patients:&#xD;
&#xD;
        - healthy-topics matched for age, recruited from the Etablissement français du sang or in&#xD;
        the Department of Internal Medicine of Nantes University Hospital&#xD;
&#xD;
        Non Inclusion Criteria:&#xD;
&#xD;
          -  ANCA-associated vasculitis with Eosinophilic granulomatosis with polyangiitis&#xD;
             (AAV-EGPA).&#xD;
&#xD;
          -  Infectious or progressive tumor pathology.&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
&#xD;
          -  Treatment with cyclophosphamide in the 6 months prior to inclusion.&#xD;
&#xD;
          -  Terminal chronic renal failure, presence of organ allograft.&#xD;
&#xD;
          -  Thrust Patients receiving corticosteroids&gt; 20 mg / d in the previous 4 weeks.&#xD;
&#xD;
          -  Inability to give informed about information (subject in emergencies, understanding of&#xD;
             the subject of difficulty, ...)&#xD;
&#xD;
          -  Minor subject, under judicial protection, guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fadi Fakhouri, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

